TCM
CASC

Tekla Capital Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Tekla Capital Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-740,769
Closed -$2.74M – 196
2017
Q4 		$2.74M Buy
740,769
+286,869
+63% +$1.17M 0.11% 114
2017
Q3 		$1.86M Buy
+453,900
New +$1.74M 0.07% 123

Tekla Capital Management's CASC Position: Q1 2018 in Review

Tekla Capital Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 740,769 shares — an estimated $2.74M sold.

Tekla Capital Management first reported a position in CASC in Q3 2017 and held it in 2 quarters. The position peaked at $2.74M in Q4 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

  • Tekla Capital Management reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Tekla Capital Management sold 740,769 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $2.74M.
  • Tekla Capital Management first reported a position in Cascadian Therapeutics, Inc. in Q3 2017 and held it in 2 quarters.
  • Tekla Capital Management's Cascadian Therapeutics, Inc. position peaked at $2.74M in Q4 2017.
  • 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Tekla Capital Management's 13F filing for Q1 2018, filed 14 May 2018.